image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 11.76
-3.33 %
$ 758 M
Market Cap
-14.33
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one EOLS stock under the worst case scenario is HIDDEN Compared to the current market price of 11.8 USD, Evolus, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one EOLS stock under the base case scenario is HIDDEN Compared to the current market price of 11.8 USD, Evolus, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one EOLS stock under the best case scenario is HIDDEN Compared to the current market price of 11.8 USD, Evolus, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EOLS

image
$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
266 M REVENUE
31.76%
-34.4 M OPERATING INCOME
30.11%
-50.4 M NET INCOME
18.26%
-18 M OPERATING CASH FLOW
47.07%
-4.82 M INVESTING CASH FLOW
-196.44%
47.4 M FINANCING CASH FLOW
6.21%
78.9 M REVENUE
29.24%
-2.31 M OPERATING INCOME
85.04%
-6.79 M NET INCOME
64.57%
4.81 M OPERATING CASH FLOW
184.03%
-1.36 M INVESTING CASH FLOW
3.40%
-1.31 M FINANCING CASH FLOW
7.27%
Balance Sheet Evolus, Inc.
image
Current Assets 151 M
Cash & Short-Term Investments 87 M
Receivables 47.7 M
Other Current Assets 16.7 M
Non-Current Assets 81.2 M
Long-Term Investments 0
PP&E 10.4 M
Other Non-Current Assets 70.8 M
37.39 %20.50 %7.18 %4.47 %30.45 %Total Assets$232.6m
Current Liabilities 63 M
Accounts Payable 9.24 M
Short-Term Debt 1.72 M
Other Current Liabilities 52 M
Non-Current Liabilities 164 M
Long-Term Debt 122 M
Other Non-Current Liabilities 42.6 M
4.07 %22.91 %53.52 %18.75 %Total Liabilities$227.0m
EFFICIENCY
Earnings Waterfall Evolus, Inc.
image
Revenue 266 M
Cost Of Revenue 84 M
Gross Profit 182 M
Operating Expenses 217 M
Operating Income -34.4 M
Other Expenses 16 M
Net Income -50.4 M
300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)266m(84m)182m(217m)(34m)(16m)(50m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.46% GROSS MARGIN
68.46%
-12.92% OPERATING MARGIN
-12.92%
-18.94% NET MARGIN
-18.94%
-913.07% ROE
-913.07%
-21.68% ROA
-21.68%
-20.35% ROIC
-20.35%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Evolus, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -50.4 M
Depreciation & Amortization 6.02 M
Capital Expenditures -1.47 M
Stock-Based Compensation 22.3 M
Change in Working Capital 0
Others 4.17 M
Free Cash Flow -19.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Evolus, Inc.
image
Wall Street analysts predict an average 1-year price target for EOLS of $24 , with forecasts ranging from a low of $20 to a high of $27 .
EOLS Lowest Price Target Wall Street Target
20 USD 70.07%
EOLS Average Price Target Wall Street Target
24 USD 104.08%
EOLS Highest Price Target Wall Street Target
27 USD 129.59%
Price
Max Price Target
Min Price Target
Average Price Target
282826262424222220201818161614141212101088Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Evolus, Inc.
image
Sold
0-3 MONTHS
2.16 M USD 5
3-6 MONTHS
156 K USD 3
6-9 MONTHS
138 K USD 2
9-12 MONTHS
6.19 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP. Highlights of the new facility include: Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based. businesswire.com - 2 weeks ago
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
Evolus to Report First Quarter Financial Results on May 7, 2025 NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To par. businesswire.com - 3 weeks ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in April of an aggregate of 30,579 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant d. businesswire.com - 1 month ago
Evolus Announces Commercial Launch of Evolysse™ NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, scheduled for Friday, April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for health. businesswire.com - 1 month ago
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the launch of its bold new campaign, “Drop the F Word,” ahead of the upcoming commercial launch of Evolysse™. Designed to challenge outdated perceptions and language in the aesthetics industry, the campaign introduces Evolysse™, a collection of injectable hyaluronic acid (HA) gels specifically designed to deliver long-lasting, natural. businesswire.com - 1 month ago
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1. The fireside chats can be accessed on the Investor Relations page of the Evolus website here. businesswire.com - 1 month ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company's common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant and vesting commencement d. businesswire.com - 1 month ago
Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript Evolus, Inc. (NASDAQ:EOLS ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - Chief Medical Officer and Head of R&D Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Gangireddy Madhumitha - Stryker Navann Ty - BNP Paribas Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Good afternoon, everyone, and thank you for standing by. seekingalpha.com - 2 months ago
Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates Evolus, Inc. (EOLS) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.14 per share a year ago. zacks.com - 2 months ago
Evolus posts quarterly profit on strong sales of cosmetic injection Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox. reuters.com - 2 months ago
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth quarter and full-year ended December 31, 2024. “We reached a significant inflection point in 2024, achieving full-year profitability1 ahead of expectations while delivering our fifth consecutive year of revenue growth exceeding 30%,” said David Moatazedi, President and Chief Executive Officer of Ev. businesswire.com - 2 months ago
8. Profile Summary

Evolus, Inc. EOLS

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 758 M
Dividend Yield 0.00%
Description Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Contact 520 Newport Center Drive, Newport Beach, CA, 92660 https://www.evolus.com
IPO Date Feb. 8, 2018
Employees 332
Officers Mr. Jeffrey J. Plumer General Counsel Mr. David Moatazedi President, Chief Executive Officer & Director Ms. Sandra Beaver Chief Financial Officer Mr. Nareg Sagherian Head of Global Investor Relations & Corporate Communications Mr. Kurt Knab Senior Vice President of Sales Ms. Jessica Novak Senior Vice President of Human Resources Ms. Tomoko Yamagishi-Dressler Chief Marketing Officer Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. Chief Medical Officer and Head of Research & Development